Vocal tract symptoms: Severity and frequency in patients on statins

dc.contributor.authorHamdan, Abdul Latif H.
dc.contributor.authorMourad, Marc M.
dc.contributor.authorFakhri, Ghina B.
dc.contributor.authorSarieddine, Doja S.
dc.contributor.authorKhalifee, Elie
dc.contributor.authorAzar, Sami T.
dc.contributor.departmentOtolaryngology/Head and Neck Surgery
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:09:24Z
dc.date.available2025-01-24T12:09:24Z
dc.date.issued2018
dc.description.abstractThe objective of the study was to analyze the frequency and severity of vocal tract symptoms in patients on statins. A total of 73 patients were enrolled in this study, 44 patients who were taking statins and 29 controls not taking statins. The severity and frequency of vocal tract discomfort was assessed using the Vocal Tract Discomfort scale. The most frequent vocal tract symptom in patients on statins was dryness followed by tightness and lump sensation. The difference in the mean of the total score and in the mean frequency of any vocal tract symptom was not significant between patients taking statins and controls. The most severe (highest mean values) vocal tract symptom in patients taking statins also was dryness followed by tightness and lump sensation. The difference in the mean of the total score and in the mean severity of any vocal tract symptom between patients taking statins and controls was not significant. This study failed to demonstrate a higher prevalence or severity of vocal tract symptoms in patients receiving statins. Despite the lack of a significant difference in the means of vocal tract discomfort symptom frequency and severity, this study carries clinical significance when considering that a higher prevalence and severity of vocal tract discomfort symptoms should alert physicians to the possible development of statin-induced myotoxicity in the laryngopharyngeal complex. © 2018 Vendome Group, LLC.
dc.identifier.eid2-s2.0-85046801075
dc.identifier.pmid29940682
dc.identifier.urihttp://hdl.handle.net/10938/32034
dc.language.isoen
dc.publisherMedquest Communications LLC
dc.relation.ispartofEar, Nose and Throat Journal
dc.sourceScopus
dc.subjectCase-control studies
dc.subjectFemale
dc.subjectHumans
dc.subjectHydroxymethylglutaryl-coa reductase inhibitors
dc.subjectMale
dc.subjectMiddle aged
dc.subjectPrevalence
dc.subjectSeverity of illness index
dc.subjectVocal cord dysfunction
dc.subjectHydroxymethylglutaryl coenzyme a reductase inhibitor
dc.subjectAdult
dc.subjectArticle
dc.subjectBurning sensation
dc.subjectControlled study
dc.subjectDisease severity
dc.subjectDry throat
dc.subjectHuman
dc.subjectMajor clinical study
dc.subjectQuestionnaire
dc.subjectSex ratio
dc.subjectThroat disease
dc.subjectThroat tightness
dc.subjectTreatment duration
dc.subjectVocal tract discomfort scale
dc.subjectCase control study
dc.subjectChemically induced
dc.subjectPathology
dc.subjectVocal cord disorder
dc.titleVocal tract symptoms: Severity and frequency in patients on statins
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2018-4260.pdf
Size:
144.33 KB
Format:
Adobe Portable Document Format